R/R DLBCL algorithm adapted from NCCN and ESMO guidelines in collaboration with clinical experts
* Currently platinum-based regimen combined with rituximab.
† Regimen depends on previous regimen, age and fitness.
‡ Includes CAR-T where locally available.
R/R, relapsed/refractory; DLBCL, diffuse large B-cell lymphoma; HSCT, haematopoietic stem cell transplant; MOA, mode of action; R-Benda, rituximab and bendamustine; 1L, first-line; 2L, second-line; 3L, third-line; SoC, standard of care; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; CAR-T, chimeric antigen receptor T-cell therapy; NCCN, National Comprehensive Cancer Network; ESMO, European Society for Medical Oncology.
- POLIVY Summary of Product Characteristics.
Date of preparation: September 2020